Access and elimination: the future of DAAs in hepatitis C
How direct-acting antivirals are transforming treatment of hepatitis C.
Articles/ Pharma Market Access/ Views and analysis
Marco Ricci
DAA, direct-acting antivirals, HCV, hepatitis C, patients, research
0 Comment
How direct-acting antivirals are transforming treatment of hepatitis C.
Articles/ Healthcare/ Pharma Market Access/ Views and analysis
Andrew McConaghie
AbbVie, Gilead, HCV, Hep C, hepatitis C, Sovaldi
0 Comment
Gilead has led a revolution in curing hepatitis C, but now faces a slowdown.
Richard Staines
ema, HCV, Hep B, hepatitis B, hepatitis C, pharmacovigilance
0 Comment
Articles/ Healthcare/ Views and analysis
Linda Banks
HCV, Hepatitis, hepatitis C, infectious diseases
0 Comment
Andrew McConaghie
AbbVie, Europe, Gilead, HCV, Hep C
0 Comment
AbbVie aiming to steal market share from Gilead